<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A nonrandom translocation between chromosomes 3 and 21, t(3;21)(q26.2;q22) has been detected in patients with a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> after treatment (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) for a primary malignant disease and in <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BC) </plain></SENT>
<SENT sid="1" pm="."><plain>In these patients, the breakpoint on chromosome 21 is at band 21q22 </plain></SENT>
<SENT sid="2" pm="."><plain>This band is also involved in the t(8;21)(q22;q22) detected in 40% of the patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> subtype M2 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M2) de novo who have an abnormal karyotype </plain></SENT>
<SENT sid="3" pm="."><plain>In the t(8;21), the AML1 gene is the site of the breakpoint on chromosome 21 </plain></SENT>
<SENT sid="4" pm="."><plain>The AML1 gene is transcribed from telomere to centromere, and in the t(8;21) the 5' part of AML1 is fused to the <z:chebi fb="0" ids="27561">ETO</z:chebi> gene on chromosome 8 to produce the chimeric AML1/<z:chebi fb="0" ids="27561">ETO</z:chebi> on the der(8) chromosome </plain></SENT>
<SENT sid="5" pm="."><plain>We found that AML1 is also rearranged in two t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients and in one <z:mp ids='MP_0005481'>CML</z:mp>-BC patient with the t(3;21), but the breakpoints are approximately 40 to 60 kb downstream to those of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M2 patients </plain></SENT>
<SENT sid="6" pm="."><plain>This region contains at least one additional exon of AML1, as determined by using an AML1 cDNA as a probe in Southern blot analysis </plain></SENT>
<SENT sid="7" pm="."><plain>The t(3;21) breakpoints for the remaining patients could not be determined because, by fluorescence in situ hybridization analysis, the breaks are outside of the region covered by the available probes </plain></SENT>
</text></document>